| scholarly article | Q13442814 |
| P2093 | author name string | Adams S | |
| Baum R | |||
| Hör G | |||
| Rink T | |||
| Usadel KH | |||
| Schumm-Dräger PM | |||
| P433 | issue | 1 | |
| P921 | main subject | fluorine | Q650 |
| positron emission tomography | Q208376 | ||
| P304 | page(s) | 79-83 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. | |
| P478 | volume | 25 |
| Q53312438 | (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. |
| Q48860405 | (68)Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin. |
| Q43289875 | (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma |
| Q44779845 | 131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging |
| Q42965034 | 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging |
| Q36342833 | 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study |
| Q38082417 | 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type |
| Q53125755 | 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. |
| Q37827752 | A new dimension of FDG-PET interpretation: assessment of tumor biology. |
| Q53094166 | A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. |
| Q46720875 | Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography |
| Q37808142 | Care for patients with multiple endocrine neoplasia type 1: the current evidence base |
| Q26849276 | Clinical applications of Gallium-68 |
| Q36142620 | Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy |
| Q40520326 | Colonic neuroendocrine carcinoma in a child |
| Q45126334 | Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours |
| Q39418313 | Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line |
| Q60652391 | Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy |
| Q53059695 | Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor. |
| Q35979079 | Correlation between Calcitonin Levels and [(18)F]FDG-PET/CT in the Detection of Recurrence in Patients with Sporadic and Hereditary Medullary Thyroid Cancer |
| Q38957569 | Cross sectional and nuclear medicine imaging of pancreatic insulinomas |
| Q53343316 | Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. |
| Q38004952 | Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis |
| Q44296937 | Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner |
| Q42124438 | Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to the World Health Organization classification. |
| Q37063180 | Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle |
| Q37150867 | Dual tracer functional characterization of metastatic gastric carcinoid |
| Q80492085 | Dynamic contrast-enhanced MR imaging |
| Q35550939 | Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. |
| Q35138836 | Evaluation of 68Ga-labeled MG7 antibody: a targeted probe for PET/CT imaging of gastric cancer |
| Q46911885 | Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy |
| Q28247667 | Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours |
| Q33744014 | Fluorine-18-fluorodihydroxyphenylalanine Positron-emission Tomography Scans of Neuroendocrine Tumors (Carcinoids and Pheochromocytomas). |
| Q53425366 | Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. |
| Q36621478 | Functional imaging of neuroendocrine tumours with PET. |
| Q42406543 | Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment |
| Q28263732 | Gastroenteropancreatic neuroendocrine tumours |
| Q60921527 | Grading of Neuroendocrine Carcinomas: Correlation of Ga-PET/CT Scan with Tissue Biomarkers |
| Q38488830 | Hybrid PET/MR imaging: physics and technical considerations |
| Q28238305 | Imaging of gastroenteropancreatic neuroendocrine tumors |
| Q45166488 | In search of an unknown primary tumour presenting with extracervical metastases: the diagnostic performance of FDG-PET. |
| Q38813559 | In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT. |
| Q53224738 | Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors. |
| Q24647838 | Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies |
| Q94446848 | Initial report of an intradural extramedullary metastasis of a pancreatic neuroendocrine tumor to the cervical spine: a case report and review of literature |
| Q33739396 | Intraoperative localization of insulinoma and normal pancreas using invisible near-infrared fluorescent light |
| Q46152235 | Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour? |
| Q34157385 | Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. |
| Q36974134 | Metastatic Gastrointestinal Carcinoid Tumor with Unknown Primary Site. |
| Q39590717 | Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs). |
| Q37730951 | Molecular imaging of neuroendocrine tumors |
| Q40093226 | Natural course of an untreated metastatic perirectal lymph node after the endoscopic resection of a rectal neuroendocrine tumor |
| Q38227725 | Neuroendocrine neoplasms of the extrahepatic bile duct: radiologic and clinical characteristics |
| Q35585146 | Neuroendocrine tumor of the gallbladder |
| Q53502873 | Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation. |
| Q43716955 | New radiolabeled CCK-8 analogues [Tc-99m-GH-CCK-8 and Tc-99m-DTPA-CCK-8]: preparation and biodistribution studies in rats and rabbits |
| Q33704417 | Nonfunctioning Periurethral Paraganglioma Incidentally Detected by FDG PET/CT |
| Q36084862 | Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. |
| Q38027393 | Nuclear medicine in NET. |
| Q60607023 | Nuklearmedizinische Diagnostik von Lebertumoren |
| Q53578474 | Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. |
| Q42254140 | PET Imaging in Recurrent Medullary Thyroid Carcinoma |
| Q46516978 | PET and paediatrics |
| Q74687069 | PET scanning in clinical oncology |
| Q37592451 | PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India |
| Q41213228 | Pancreatic gangliocytic paraganglioma harboring lymph node metastasis: a case report and literature review |
| Q37354131 | Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment |
| Q37301288 | Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). |
| Q34277286 | Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer |
| Q81312570 | Primary carcinoid tumor of prostate presenting with bone marrow metastases |
| Q48874469 | Progressive cognitive decline and neuropathy in a sailor |
| Q37728328 | Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions |
| Q39773838 | Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors |
| Q36301116 | Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas |
| Q38233342 | Role of (18) F-FDOPA PET/CT imaging in endocrinology |
| Q37994083 | Role of PET/CT in the functional imaging of endocrine pancreatic tumors |
| Q44492794 | Somatostatin analogue scintigraphy in Merkel cell tumours |
| Q42757356 | Somatostatin receptor-based imaging and therapy of digestive endocrine tumors |
| Q36661451 | Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI. |
| Q34198796 | Standardisation of imaging in neuroendocrine tumours: results of a European delphi process |
| Q33967697 | Submucosal small-cell neuroendocrine carcinoma of the larynx detected using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography: A case report and review of the literature |
| Q35525690 | The next generation of positron emission tomography radiopharmaceuticals in oncology. |
| Q43266606 | The role of integrated (18)F-FDG PET/CT in identification of ectopic ACTH secretion tumors |
| Q34273556 | The role of nuclear medicine in the evaluation of pancreatic disease |
| Q45940015 | The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. |
| Q39271421 | Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated |
| Q36066047 | Update of PET and PET/CT for hepatobiliary and pancreatic malignancies |
| Q45045306 | Whole-body tumor staging: MRI or FDG-PET/CT? |
| Q46351387 | [18F]FDG PET/CT in pancreatic neuroendocrine tumours associated with von Hippel Lindau Syndrome |
| Q81160899 | [Endocrine pancreas] |
| Q53520582 | [PET in thyroid cancers]. |
| Q44121876 | [Positron emission tomography (PET) in clinical oncology [Part III]] |
| Q53531661 | [Positron emission tomography (PET) in gastrointestinal cancer]. |
| Q53515442 | [Positron-emission tomography/computed tomography: artifacts and pitfalls in cancer patients]. |
| Q53065428 | [The relevance of PET/CT for the surgical management of neuroendocrine neoplasms]. |
| Q37990397 | ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. |
Search more.